대한뉴팜

Daehan New Pharm Co., Ltd. (CEO Bae Kun-Woo) successfully completed the GMP inspection conducted by the Ethiopian Ministry of Health in June and received final approval of compliance on July 16. As a result, the company expects to export more than USD 1–2 million worth of finished pharmaceuticals and veterinary medicines annually to Ethiopia in the coming years. Daehan New Pharm has consistently exported veterinary medicines to Ethiopia since 2002, starting with USD 320,000 and maintaining annual exports of USD 400,000–500,000. With this GMP approval, the company has now established a foothold to supply its core human pharmaceutical products, including cephalosporin antibiotics and anticancer drugs, to the Ethiopian market. Although Ethiopia is a developing country, it manages its pharmaceutical regulations in accordance with international standards, including WHO GMP criteria. Therefore, the outcome of this inspection carries significant meaning. Moreover, due to the declining presence of competing supplier nations such as India, Pakistan, and China in the Ethiopian pharmaceutical import market, the company’s export prospects are looking even brighter. Daehan New Pharm currently exports cephalosporin-based pharmaceuticals such as ceftriaxone, ceftazidime, and cefpodoxime to more than 20 countries worldwide, including Vietnam, Pakistan, and Cuba. The company is also actively expanding exports of major products such as streptokinase (a thrombolytic agent), and anticancer drugs including carboplatin, dacarbazine, and dactinomycin. Meanwhile, in November 2007, Daehan New Pharm received the USD 5 Million Export Tower Award at the 44th Trade Day celebration. The company continues to strengthen its overseas partnerships and develop strategic export products with strong market potential, aiming to achieve USD 10 million in annual exports within the next few years.

Daehan New Pharm held its 2008 New Year’s kickoff ceremony on Wednesday, January 2, with all executives and employees in attendance at both the headquarters and the manufacturing plant. During the ceremony at the headquarters, seven employees, including Deputy Manager Kim Jong-seong from the Animal Health Division’s Development and Marketing Department, received recognition awards for exemplary performance. The company adopted the slogan “United for Profit, Committed to Goals with Passion” for the year. In his New Year’s address, President Park Myung-rae expressed his expectation that many challenges would arise in the coming year but emphasized that all employees must achieve the company’s business objectives through thorough planning and strong dedication. Following the ceremony, Executive Director Seol Geun-dong delivered a special lecture for the management team on the topic “Eight Characteristics of Successful People.” Meanwhile, the company had held its year-end closing ceremony separately at both the headquarters and the plant on December 31.

As of November 26, 2007, Mr. Seol Geun-dong was appointed Executive Director in charge of Academic Development and Marketing.

The company will be awarded the 'USD 5 Million Export Tower' at the 44th Trade Day ceremony. The award ceremony will be held on Friday, November 30, 2007 at 10 a.m. in the Swingspace Hall on the 3rd floor of COEX.

As of November 5, 2007, Mr. Ryu Jeong-seok was appointed Director in charge of Business Planning and Finance.

Daehan New Pharm Co., Ltd. 23rd Anniversary Ceremony 1. Date: Saturday, October 20, 2007, 09:00–16:30 2. Venue: Cheongho Human Resources Development Center (located in Hwaseong, Gyeonggi Province) 3. Main Events: Company founding ceremony and sports activities 4. Long-Service Awards (Total of 5 recipients, 10-Year Service Award) 1) Won Hoo-jae, Manager, Quality Control Team, Production Division 2) Kim Young-gil, Assistant Manager, Solid Preparation Team, Production Division 3) Shin Hee-joon, Staff, Facility Team, Production Division 4) Heo Young-soon, Staff, Bio Team, Production Division 5) Kim Soon-hee, Staff, Sales Planning & Management Section, Pharmaceutical Business Division*Award Details: Certificate of merit and a 10-don (approx. 37.5g) pure gold lucky key

1. Purpose: To enhance motivation and company loyalty through overseas training of outstanding employees 2. Training period/location: October 12–16, 2007 (5 days, 3 nights) / Bangkok, Pattaya 3. Number of participants: 16 total, including Manager Lee Eun-woo of the Animal Health Division and 15 others

The product contains Vitamin C, succinic acid, and other ingredients. In addition to the original packaging of 6 tablets, a 2-tablet pack for single use has been newly introduced. Daehan New Pharm released ‘Rus.id Anti-F Vitamin C Classic’. This product is a new brand of RU*21, which was first introduced domestically through media coverage in 2004. It has undergone clinical trials at Russia’s national research institute, holds a Russian patent, and is registered with the Russian Ministry of Health. In addition to the original 6-tablet pack, Daehan New Pharm has now launched a single-dose pack containing 2 tablets. According to the company, Rus.id is formulated with vitamin C, succinic acid, fumaric acid, and glutamine, which help eliminate harmful free radicals from the body, suppress and break down acetaldehyde generated by alcohol consumption. Recommended dosage: Take 2 tablets before drinking, 2 tablets two hours later, and 2 tablets the next day to help relieve hangover symptoms. The product is exclusively imported from Russia’s SKS-Aliance and sold through pharmacies. The company also actively engages in sports marketing, including sponsorship of Seongnam Ilhwa, a leading team in Korea’s K-League.

Agenda Item 1: Approval of the 23rd Fiscal Year Balance Sheet and Income Statement - Approved as Proposed1. Approval of Financial Statements1. Financials for the 23rd Fiscal Year (unit: million KRW)- Total Assets52,440- Sales Revenue52,120- Total Liabilities25,719- Operating Profit3,768- Capital Stock4,300- Net Income for the Period1,632- Total Equity26,721- Earnings Per Share (KRW)190* External Auditor's Opinion: UnqualifiedUnqualifiedAgenda Item 2: Approval of the Appropriation of Retained Earnings for the 23rd Fiscal Year - Approved as Proposed2. Dividend Resolutiona. Cash DividendsDividend per Common Share (KRW)Common ShareYear-end Dividend50Interim/Quarterly Dividends- Preferred SharesYear-end Dividend- Interim/Quarterly Dividends-Total Dividend Amount (KRW)430,000,000Agenda Item 3: Election of Directors - Reappointment of Director Myungrae ParkAgenda Item 4: Election of Auditor - Reappointment of Auditor Seongsook KimAgenda Item 5: Approval of Director Remuneration Limit - Approved as Proposed (KRW 1.5 Billion)Agenda Item 6: Approval of Auditor Remuneration Limit - Approved as Proposed (KRW 100 Million)